Related Experiment Videos
Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies
1Center for Development of Cancer Therapeutics, Parkville, Victoria 3050, Australia. basser@licre.ludwig.edu.au
Abstract:
Megakaryocyte growth and development factor (MGDF), an Mpl ligand, recently entered clinical trials worldwide and has been demonstrated to have potent biological activity. MGDF administration causes a dose-dependent increase in platelet count but no effect on white cell count or hematocrit. These platelets are morphologically and functionally normal. When administered following moderately myelosuppressive chemotherapy, MGDF significantly enhances platelet recovery, although scheduling in relation to chemotherapy may be important in optimizing the full effects. MGDF mobilizes progenitor cells of multiple hematopoietic lineages, and may enhance the effects of filgrastim on peripheral blood progenitor cell levels after chemotherapy. MGDF is well tolerated and does not cause toxicity similar to that observed with other thrombopoietic cytokines. Numerous studies are under way to help determine the precise role of MGDF in clinical practice.
Insights
Megakaryocyte growth and development factor (MGDF) effectively increases platelet counts without affecting other blood cells. This thrombopoietic agent shows promise in enhancing platelet recovery after chemotherapy.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Megakaryocyte growth and development factor (MGDF), an Mpl ligand, is under clinical investigation.
- MGDF exhibits potent biological activity relevant to platelet production.
Purpose of the Study:
- To evaluate the effects of MGDF on platelet count, blood cell counts, and hematocrit.
- To assess MGDF's efficacy in enhancing platelet recovery following myelosuppressive chemotherapy.
- To investigate MGDF's potential to mobilize hematopoietic progenitor cells.
Main Methods:
- Administration of MGDF to assess dose-dependent effects on platelet counts.
- Evaluation of MGDF's impact on white cell count and hematocrit.
- Assessment of platelet morphology and function post-MGDF administration.
- Analysis of MGDF's role in platelet recovery after chemotherapy.
- Investigation of MGDF's effect on progenitor cell mobilization.
Main Results:
- MGDF administration led to a dose-dependent increase in platelet count.
- No significant effects were observed on white cell count or hematocrit.
- Platelets produced under MGDF treatment were morphologically and functionally normal.
- MGDF significantly enhanced platelet recovery when administered after chemotherapy.
- MGDF mobilized progenitor cells from multiple hematopoietic lineages.
- MGDF was well tolerated with no observed toxicity similar to other thrombopoietic cytokines.
Conclusions:
- MGDF is a potent thrombopoietic agent with a favorable safety profile.
- MGDF demonstrates significant potential in improving platelet recovery after chemotherapy.
- Further clinical studies are necessary to define the optimal role of MGDF in practice.